A Study of LY3493269 in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-03

Study Completion Date

2021-11-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to evaluate the safety and tolerability of LY3493269 in healthy participants. The blood tests will be performed to check how much LY3493269 gets into the bloodstream, how long the body takes to eliminate it and how body handles LY3493269. The study will last up to approximately 71 days for each participant, including screening

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants

NCT04178733

Healthy

COMPLETED PHASE1

A Multiple-Dose Study of LY3493269 in Healthy Participants

NCT05794243

Healthy

TERMINATED PHASE1

A Safety Study of LY3372689 in Healthy Participants

NCT04106206

Healthy

COMPLETED PHASE1

A Study of LY3532226 in Healthy Participants

NCT04923269

Healthy

COMPLETED PHASE1

A Study to Compare Two Formulations of LY3819469 in Healthy Participants

NCT05932446

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Participants received placebo orally once daily (QD) for three consecutive days.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally.

8 Milligrams (mg) LY3493269 + 600 mg Salcaprozate Sodium (SNAC)

Participants received 8 mg LY3493269 and 600 mg SNAC QD administered orally for three consecutive days.

Group Type EXPERIMENTAL

LY3493269

Intervention Type DRUG

Administered orally.

Salcaprozate Sodium

Intervention Type DRUG

Administered orally.

24 mg LY3493269 + 600 mg SNAC

Participants received 24 mg LY3493269 and 600 mg SNAC QD administered orally for three consecutive days.

Group Type EXPERIMENTAL

LY3493269

Intervention Type DRUG

Administered orally.

Salcaprozate Sodium

Intervention Type DRUG

Administered orally.

12 mg LY3493269 + 300 mg SNAC

Participants received 12 mg LY3493269 and 300 mg SNAC QD administered orally for three consecutive days.

Group Type EXPERIMENTAL

LY3493269

Intervention Type DRUG

Administered orally.

Salcaprozate Sodium

Intervention Type DRUG

Administered orally.

4 mg LY3493269 + 300 mg SNAC

Participants received 4 mg LY3493269 and 300 mg SNAC QD administered orally for three consecutive days.

Group Type EXPERIMENTAL

LY3493269

Intervention Type DRUG

Administered orally.

Salcaprozate Sodium

Intervention Type DRUG

Administered orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3493269

Administered orally.

Intervention Type DRUG

Placebo

Administered orally.

Intervention Type DRUG

Salcaprozate Sodium

Administered orally.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Are male or female not of childbearing potential
2. Body mass index within the range of 19.0 to 40.0 kilograms per square meter (kg/m²) (inclusive)
3. Participants who are healthy as determined through medical evaluation including screening medical history, physical examination, vital signs, clinical laboratory tests, and electrocardiogram (ECG)
4. Have clinical laboratory test results within normal reference range for the population or clinical research unit (CRU), or results with acceptable deviations that are judged to be not clinically significant by the investigator
5. Have venous access sufficient to allow blood sampling as per the protocol.

Exclusion Criteria

1. Have a significant history of or current CV (for example, myocardial infarction, congestive heart failure, cerebrovascular accident, venous thromboembolism, etc.), respiratory, renal, GI, endocrine, hematological (including history of thrombocytopenia), or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk while taking the IP; or of interfering with the interpretation of data
2. Have undergone any form of bariatric surgery
3. Have a history of gastrointestinal (GI) bleeding or duodenal ulcers
4. Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
5. Have a history of acute or chronic pancreatitis, or elevation in serum lipase and/or amylase levels greater than 1.5 times the upper limit of normal (ULN)
6. Have clinical signs or symptoms of liver disease, acute or chronic hepatitis
7. Have evidence of significant active neuropsychiatric disease as determined by the investigator
8. Have been treated with prescription drugs that promote weight loss within 3 months prior to screening
9. Are currently enrolled in a clinical study involving an IP or any other type of medical research judged not to be scientifically or medically compatible with this study
10. Have participated within the past 30 days of screening in a clinical study involving an investigational product (IP); at least 5 half-lives or 30 days, whichever is longer, should have passed
11. Have an abnormality in the 12-lead ECG at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG (QT) data analysis, such as a QTcF greater than (\>) 450 milliseconds (msec) for males and \> 470 msec for females, short PR interval (\< 120 msec), or PR interval \> 220 msec, second and third atrioventricular block, intraventricular conduction delay with QRS \>120 msec, right bundle branch block, left bundle branch block or Wolff-Parkinson-White syndrome
12. Have serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>1.5 times (X) ULN or total bilirubin level (TBL) \>1.5X ULN
13. Show evidence of HIV infection and/or positive human HIV antibodies
14. Show evidence of hepatitis C and/or positive hepatitis C antibody
15. Show evidence of hepatitis B, positive hepatitis B core antibody, and/or positive hepatitis B surface antigen
16. Have donated blood of more than 450 mL, or have participated in a clinical study that required similar blood volume drawn within the past 3 calendar months
17. Have known allergies to LY3493269, related compounds, or any components of the formulation (including SNAC), or a history of significant atopy

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes